Immunovant (IMVT) Stock Price, News & Analysis

Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Key Stats

• Today's Range: $15.86 to $16.70
• 50-Day Range: $13.78 to $16.77
• 52-Week Range: $12.72 to $34.47
• Volume: 403,227 shs
• Average Volume: 1.21 million shs
• Market Capitalization: $2.76 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.33
• Consensus Rating: Moderate Buy

Immunovant Stock Analysis - MarketRank™

Immunovant scored higher than 39% of companies evaluated by MarketBeat, and ranked 723rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immunovant has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Immunovant has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immunovant are expected to decrease in the coming year, from ($2.69) to ($3.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunovant is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunovant is -6.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunovant has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.05% of the float of Immunovant has been sold short.

Short Interest Ratio / Days to Cover

Immunovant has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunovant has recently decreased by 8.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunovant does not currently pay a dividend.

Dividend Growth

Immunovant does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

29.05% of the float of Immunovant has been sold short.

Short Interest Ratio / Days to Cover

Immunovant has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunovant has recently decreased by 8.12%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.88

News Sentiment

Immunovant has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Immunovant this week, compared to 6 articles on an average week.

Search Interest

10 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $596,619.00 in company stock.

Percentage Held by Insiders

Only 5.90% of the stock of Immunovant is held by insiders.

Percentage Held by Institutions

47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMVT Stock Analysis - Frequently Asked Questions

How have IMVT shares performed this year?

Immunovant's stock was trading at $24.77 at the beginning of 2025. Since then, IMVT shares have decreased by 33.3% and is now trading at $16.5330.
View the best growth stocks for 2025 here.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings data on Thursday, May, 29th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.08. The company earned $0.16 million during the quarter.

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/29/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMVT
• CIK: 1764013
• Web: www.immunovant.com
• Phone: 917-580-3099
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $38.33
• High Stock Price Target: $53.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +139.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$413.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -80.60%
• Return on Assets: -71.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.16
• Quick Ratio: 11.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.16 per share
• Price / Book: 3.85

Miscellaneous

• Outstanding Shares: 170,920,000
• Free Float: 160,839,000
• Market Cap: $2.73 billion
• Optionable: Optionable
• Beta: 0.61